ABSTRACT
It is now well established that tumours undergo changes in cellular metabolism1. As this can reveal tumour cell vulnerabilities and because many tumours exhibit enhanced glucose uptake2, we have been interested in how tumour cells respond to different forms of sugar. Here we report that the monosaccharide mannose causes growth retardation in several tumour types in vitro, and enhances cell death in response to major forms of chemotherapy. We then show that these effects also occur in vivo in mice following the oral administration of mannose, without significantly affecting the weight and health of the animals. Mechanistically, mannose is taken up by the same transporter(s) as glucose3 but accumulates as mannose-6-phosphate in cells, and this impairs the further metabolism of glucose in glycolysis, the tricarboxylic acid cycle, the pentose phosphate pathway and glycan synthesis. As a result, the administration of mannose in combination with conventional chemotherapy affects levels of anti-apoptotic proteins of the Bcl-2 family, leading to sensitization to cell death. Finally we show that susceptibility to mannose is dependent on the levels of phosphomannose isomerase (PMI). Cells with low levels of PMI are sensitive to mannose, whereas cells with high levels are resistant, but can be made sensitive by RNA-interference-mediated depletion of the enzyme. In addition, we use tissue microarrays to show that PMI levels also vary greatly between different patients and different tumour types, indicating that PMI levels could be used as a biomarker to direct the successful administration of mannose. We consider that the administration of mannose could be a simple, safe and selective therapy in the treatment of cancer, and could be applicable to multiple tumour types.
Subject(s)
Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Mannose/metabolism , Mannose/pharmacology , Neoplasms/drug therapy , Neoplasms/metabolism , Administration, Oral , Animals , Apoptosis/drug effects , Biomarkers, Tumor/metabolism , Body Weight/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Down-Regulation/drug effects , Drug Synergism , Female , Glucose/metabolism , Glycolysis/drug effects , Humans , Mannose/administration & dosage , Mannose/therapeutic use , Mannose-6-Phosphate Isomerase/deficiency , Mannose-6-Phosphate Isomerase/genetics , Mannose-6-Phosphate Isomerase/metabolism , Mannosephosphates/metabolism , Mice , Mice, Inbred C57BL , Mice, Nude , Myeloid Cell Leukemia Sequence 1 Protein/metabolism , Neoplasms/classification , Neoplasms/pathology , RNA Interference , bcl-X Protein/metabolismABSTRACT
BACKGROUND: Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician's choice standard of care in patients with recurrent low-grade serous carcinoma. METHODS: This international, randomised, open-label, multicentre, phase 2/3 trial was done at 84 hospitals in the USA and UK. Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen, but not all five standard-of-care drugs, and had received an unlimited number of previous regimens. Patients with serous borderline tumours or tumours containing low-grade serous and high-grade serous carcinoma were excluded. Eligible patients were randomly assigned (1:1) to receive either oral trametinib 2 mg once daily (trametinib group) or one of five standard-of-care treatment options (standard-of-care group): intravenous paclitaxel 80 mg/m2 by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40-50 mg/m2 by body surface area once every 4 weeks; intravenous topotecan 4 mg/m2 by body surface area on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. Randomisation was stratified by geographical region (USA or UK), number of previous regimens (1, 2, or ≥3), performance status (0 or 1), and planned standard-of-care regimen. The primary endpoint was investigator-assessed progression-free survival while receiving randomised therapy, as assessed by imaging at baseline, once every 8 weeks for 15 months, and then once every 3 months thereafter, in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02101788, and is active but not recruiting. FINDINGS: Between Feb 27, 2014, and April 10, 2018, 260 patients were enrolled and randomly assigned to the trametinib group (n=130) or the standard-of-care group (n=130). At the primary analysis, there were 217 progression-free survival events (101 [78%] in the trametinib group and 116 [89%] in the standard-of-care group). Median progression-free survival in the trametinib group was 13·0 months (95% CI 9·9-15·0) compared with 7·2 months (5·6-9·9) in the standard-of-care group (hazard ratio 0·48 [95% CI 0·36-0·64]; p<0·0001). The most frequent grade 3 or 4 adverse events in the trametinib group were skin rash (17 [13%] of 128), anaemia (16 [13%]), hypertension (15 [12%]), diarrhoea (13 [10%]), nausea (12 [9%]), and fatigue (ten [8%]). The most frequent grade 3 or 4 adverse events in the standard-of-care group were abdominal pain (22 [17%]), nausea (14 [11%]), anaemia (12 [10%]), and vomiting (ten [8%]). There were no treatment-related deaths. INTERPRETATION: Trametinib represents a new standard-of-care option for patients with recurrent low-grade serous carcinoma. FUNDING: NRG Oncology, Cancer Research UK, Target Ovarian Cancer, and Novartis.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma, Ovarian Epithelial/drug therapy , Ovarian Neoplasms/drug therapy , Pyridones/administration & dosage , Pyrimidinones/administration & dosage , Administration, Oral , Adult , Aged , Carcinoma, Ovarian Epithelial/pathology , Female , Humans , MAP Kinase Kinase 1/metabolism , Middle Aged , Neoplasm Grading , Neoplasm Recurrence, Local/pathology , Ovarian Neoplasms/pathology , Paclitaxel/administration & dosage , Progression-Free Survival , Standard of Care , Treatment Outcome , United Kingdom , United StatesABSTRACT
BACKGROUND: Hormonal therapies are commonly prescribed to patients with metastatic granulosa cell tumours (GCT), based on high response rates in small retrospective studies. Aromatase inhibitors (AIs) are reported to have high response rates and an accepted treatment option. We report the results of a phase 2 trial of an AI in recurrent/metastatic GCTs. METHODS: 41 patients with recurrent ER/PR + ve GCT received anastrozole 1 mg daily until progression or unacceptable toxicity. The primary endpoint was clinical benefit rate (CBR) at 12 weeks, evaluated by RECIST1.1 criteria. Secondary endpoints included progression-free survival (PFS), CBR duration, quality of life and toxicity. RESULTS: The CBR at 12 weeks in 38 evaluable patients was 78.9%, which included one (2.6%; 95% CI: 0.5-13.5%) partial response and 76.3% stable disease. Two additional patients without measurable disease were stable, based on inhibin. Median PFS was 8.6 m (95% CI 5.5-13.5 m). There were delayed responses observed after 12 weeks with a total of 4 pts. (10.5%; 95% CI 4.2%-24.1%) with a RECIST partial response; 23 (59%) patients were progression-free at 6 months. The adverse effects were predominantly low grade. CONCLUSIONS: This is the first prospective trial of hormonal therapy in GCTs. Although there was a high CBR, the objective response rate to anastrozole was much lower than the pooled response rates of >70% to AIs reported in most retrospective series and case reports. PARAGON demonstrates the importance of prospective trials in rare cancers and the need to reconsider the role of AIs as single agents in GCTs.
Subject(s)
Anastrozole/therapeutic use , Granulosa Cell Tumor/drug therapy , Neoplasm Recurrence, Local/drug therapy , Ovarian Neoplasms/drug therapy , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Sex Cord-Gonadal Stromal Tumors/drug therapy , Adult , Aged , Female , Granulosa Cell Tumor/chemistry , Granulosa Cell Tumor/mortality , Humans , Middle Aged , Neoplasm Recurrence, Local/chemistry , Neoplasm Recurrence, Local/mortality , Ovarian Neoplasms/chemistry , Ovarian Neoplasms/mortality , Quality of Life , Sex Cord-Gonadal Stromal Tumors/chemistry , Sex Cord-Gonadal Stromal Tumors/mortalityABSTRACT
PURPOSE OF REVIEW: COVID-19 pandemics have severely affected Latin America. It has resulted in SARS-CoV-2-associated clinical adverse outcomes, but also in social and economic deterioration. Consequently, it generated a significant negative impact on organ donation and kidney transplantation (KTx) activity in our region, leading to a negative impact on these patients' survival and quality of life. For this reason, this article aimed to describe applicable logistics, organizational and clinical strategies to mitigate the effect of the COVID-19 pandemic on kidney donation and transplantation in our region. RECENT FINDINGS: Absenteeism to hemodialysis sessions in patients with end-stage renal disease has been described in up to 54% in Latin America. Not surprisingly, there was a reduction in organ donation and transplants between 21 and 59%. Also, there is a higher incidence of COVID-19 positive tests in the waiting list population than KTx recipients (9.9%). However, there was a higher mortality rate in KTx recipients than the waiting list population (32%). Additionally, 59% of living donor kidney transplant programs suspended the evaluation of new donors due to the COVID-19 pandemic. Throughout this manuscript, we summarize some practical tips to resume organ donation and KTx during pandemics in Latin America, such as selecting healthy donors and recipients, universal SARS-CoV-2 screening, implementing COVID-19 accessible pathways, and telehealth as a standard, and postpone all non-urgent visits.
Subject(s)
COVID-19 , Kidney Transplantation , Tissue and Organ Procurement , Humans , Latin America/epidemiology , Pandemics , Quality of Life , SARS-CoV-2ABSTRACT
OBJECTIVES: The purpose of this study was to assess if the use of intraoral positioning guides could increase the reproducibility of color measurements with a dental spectrophotometer. METHODS: Twenty-three subjects were selected, and positioning guides for the maxillary arch of each participant were fabricated with clear 4 mm thermo-sheets. One orifice was made in the center of the clinical crown of the upper-right central incisor and another in the canine, with an external 6 mm diameter trephine. Color measurements were performed with a Vita EasyShade Compact IV dental spectrophotometer by the same operator in the same conditions. Forty measurements were taken per patient, 20 for each tooth, 10 with a positioning guide, and 10 without one. Before each measurement, the spectrophotometer was calibrated following the manufacturer's instructions. RESULTS: Using the Wilcoxon test to evaluate nonparametric variables, there are statistically significant differences (P < .05) between the use or not of positioner for color recording with spectrophotometer. Greater repeatability of the measurements is obtained using repositioning split. CONCLUSIONS: Within the limitations of this study, the use of positioning guides provides greater reproducibility in spectrophotometer measurements for all parameters of tooth 11 and for some parameters of tooth 13. CLINICAL SIGNIFICANCE: The use of a positioning guide for color measurement with a dental spectrophotometer allows a greater reproducibility of the measurements to be obtained. Achieving repeatable measurements is essential for studying the same area of the tooth, for example, in bleaching treatments and in color checks for prosthetic treatments.
Subject(s)
Prosthesis Coloring , Splints , Color , Humans , Reproducibility of Results , SpectrophotometryABSTRACT
To assess the excess risk of HPV-associated cancer (HPVaC) in two at-risk groups-women with a previous diagnosis of high grade cervical intraepithelial neoplasia (CIN3) and both men and women treated for non-cervical pre-invasive anogenital disease. All CIN3 cases diagnosed in 1989-2015 in Scotland were extracted from the Scottish cancer registry (SMR06). All cases of pre-invasive penile, anal, vulval, and vaginal disease diagnosed in 1990-2015 were identified within the NHS pathology databases in the two largest NHS health boards in Scotland. Both were linked to SMR06 to extract subsequent incidence of HPVaC following the diagnosis of CIN3 or pre-invasive disease. Standardised incidence ratios were calculated for the risk of acquiring HPVaC for the two at-risk groups compared to the general Scottish population. Among 69,714 females in Scotland diagnosed with CIN3 (890,360.9 person-years), 179 developed non-cervical HPVaC. CIN3 cases were at 3.2-fold (95% CI: 2.7 to 3.7) increased risk of developing non-cervical HPVaC, compared to the general female population. Among 1,235 patients diagnosed with non-cervical pre-invasive disease (9,667.4 person-years), 47 developed HPVaC. Individuals with non-cervical pre-invasive disease had a substantially increased risk of developing HPVaC - 15.5-fold (95% CI: 11.1 to 21.1) increased risk for females and 28-fold (11.3 to 57.7) increased risk for males. We report a significant additional risk of HPV-associated cancer in those have been diagnosed with pre-invasive HPV-associated lesions including but not confined to the cervix. Uncovering the natural history of pre-invasive disease has potential for determining screening, prevention and treatment.
Subject(s)
Genital Neoplasms, Female/virology , Genital Neoplasms, Male/virology , Papillomavirus Infections/epidemiology , Precancerous Conditions/epidemiology , Uterine Cervical Dysplasia/epidemiology , Uterine Cervical Neoplasms/epidemiology , Adult , Aged , Anal Canal/pathology , Female , Genital Neoplasms, Female/epidemiology , Genital Neoplasms, Male/epidemiology , Humans , Incidence , Male , Middle Aged , Papillomavirus Infections/complications , Penis/pathology , Retrospective Studies , Scotland/epidemiology , Vagina/pathology , Vulva/pathologyABSTRACT
BACKGROUND: The clinical benefit rate with aromatase inhibitors and the impact of treatment on quality of life (QOL) in endometrial cancer is unclear. We report the results of a phase 2 trial of anastrozole in endometrial cancer. METHODS: Investigator initiated single-arm, open label trial of anastrozole, 1â¯mg/d in patients with ER and/or PR positive hormonal therapy naive metastatic endometrial cancer. Patients were treated until progressive disease (PD) or unacceptable toxicity. The primary end-point was clinical benefit (responseâ¯+â¯stable disease) at 3â¯months. Secondary endpoints include progression-free survival (PFS), quality of life (QOL) and toxicity. RESULTS: Clinical benefit rate in 82 evaluable patients at 3â¯months was 44% (95% CI: 34-55%) with a best response by RECIST of partial response in 6 pts. (7%; 95% CI: 3-15%). The median PFS was 3.2â¯months (95% CI: 2.8-5.4). Median duration of clinical benefit was 5.6â¯months (95% CI: 3.0-13.7). Treatment was well tolerated. Patients who had clinical benefit at 3â¯months reported clinically significant improvements in several QOL domains compared to those with PD; this was evident by 2â¯months including improvements in: emotional functioning (39 vs 6%: pâ¯=â¯0.002), cognitive functioning (45 vs 19%: pâ¯=â¯0.021), fatigue (47 vs 19%: pâ¯=â¯0.015) and global health status (42 vs 9%: pâ¯=â¯0.003). CONCLUSION: Although the objective response rate to anastrozole was relatively low, clinical benefit was observed in 44% of patients with ER/PR positive metastatic endometrial cancer and associated with an improvement in QOL.
Subject(s)
Anastrozole/therapeutic use , Endometrial Neoplasms/drug therapy , Endometrial Neoplasms/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Adult , Aged , Aged, 80 and over , Endometrial Neoplasms/pathology , Female , Humans , Immunohistochemistry , Middle Aged , Neoplasm Staging , Progression-Free Survival , Quality of LifeABSTRACT
The discovery, structure-activity relationships, and optimization of a novel class of fatty acid synthase (FASN) inhibitors is reported. High throughput screening identified a series of substituted piperazines with structural features that enable interactions with many of the potency-driving regions of the FASN KR domain binding site. Derived from this series was FT113, a compound with potent biochemical and cellular activity, which translated into excellent activity in in vivo models.
Subject(s)
Fatty Acid Synthases/antagonists & inhibitors , Piperazines/chemistry , Administration, Oral , Animals , Binding Sites , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Evaluation, Preclinical , Fatty Acid Synthases/metabolism , Half-Life , Humans , Malonyl Coenzyme A/metabolism , Mice , Mice, Nude , Molecular Docking Simulation , Neoplasms/drug therapy , Neoplasms/metabolism , Piperazines/administration & dosage , Piperazines/pharmacokinetics , Piperazines/pharmacology , Protein Structure, Tertiary , Rats , Structure-Activity RelationshipABSTRACT
It is universally accepted that high-risk human papillomavirus (HR-HPV) is the cause of cervical dysplasia and cancer. More recently, it has been shown that HPV is also a marker of clinical outcome in oropharyngeal cancer. However, contemporary information is lacking on both the prevalence of HPV infection in vulvar cancer (VSCC), its precursor lesion, vulvar intraepithelial neoplasia (VIN) and the influence of HPV-status on the prognosis of this malignancy. We have conducted a detailed population-based study to examine rates of progression of VIN to VSCC, type-specific HPV prevalence in vulvar disease and the influence of HPV status on clinical outcome in VSCC. We observed that the age at which women are diagnosed with VSCC is falling and there is a significant time gap between first diagnosis of VIN and progression to invasive disease. HR-HPV infection was detected in 87% (97/112) cases of VIN and 52% cases (32/62) of VSCC. The presence of HR-HPV in squamous intraepithelial lesion was associated with lower rates of progression to invasive cancer (hazard ratio, 0.22, p = 0.001). In the adjusted analysis, HR-HPV was associated with improved progression-free survival of VSCC compared to those with HPV negative tumours (hazard ratio, 0.32, p = 0.02).
Subject(s)
Carcinoma, Squamous Cell/virology , Papillomaviridae/isolation & purification , Papillomavirus Infections/virology , Vulvar Neoplasms/virology , Adult , Aged , Carcinoma in Situ/mortality , Carcinoma in Situ/therapy , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/therapy , DNA, Viral/analysis , Databases, Factual , Disease Progression , Female , Genotype , Humans , Kaplan-Meier Estimate , Lichen Sclerosus et Atrophicus/epidemiology , Lichen Sclerosus et Atrophicus/virology , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Papillomaviridae/genetics , Papillomavirus Infections/mortality , Papillomavirus Infections/therapy , Prevalence , Scotland/epidemiology , Smoking/epidemiology , Treatment Outcome , Vulvar Neoplasms/mortality , Vulvar Neoplasms/therapyABSTRACT
The total syntheses of 12-epoxyobtusallene IV, 12-epoxyobtusallene II, obtusallene X, marilzabicycloallene C, and marilzabicycloallene D as halogenated C15-acetogenin 12-membered bicyclic and tricyclic ether bromoallene-containing marine metabolites from Laurencia species are described. Two enantiomerically pure C4-epimeric dioxabicyclo[8.2.1]tridecenes were synthesized by E-selective ring-closing metathesis where their absolute stereochemistry was previously set via catalytic asymmetric homoallylic epoxidation and elaborated via regioselective epoxide-ring opening and diastereoselective bromoetherification. Epimeric face-selective oxidation of their Δ12,13 olefins followed by bromoallene installation allowed access to the oppositely configured 12,13-epoxides of 12-epoxyobtusallene II and 12-epoxyobtusallene IV. Subsequent exploration of their putative biomimetic oxonium ion formation-fragmentations reactions revealed diastereodivergent pathways giving marilzabicycloallene C and obtusallene X, respectively. The original configurations of the substrates evidently control oxonium ion formation and their subsequent preferred mode of fragmentation by nucleophilic attack at C9 or C12. Quantum modeling of this stereoselectivity at the ωB97X-D/Def2-TZVPPD/SCRF = methanol level revealed that in addition to direction resulting from hydrogen bonding, the dipole moment of the ion-pair transition state is an important factor. Marilzabicycloallene D as a pentahalogenated 12-membered bicyclic ether bromoallene was synthesized by a face-selective chloronium ion initiated oxonium ion formation-fragmentation process followed by subsequent bromoallene installation.
ABSTRACT
Multifocal squamous cervical carcinomas account for up to 25% of IA1 tumors identified on excisional biopsy, yet there are no uniformly accepted histopathologic criteria for defining and staging these lesions. Here, we use a strict case definition and meticulous specimen processing from colposcopist to pathologist to identify and follow-up 25 cases of multifocal IA1 cervical squamous carcinomas identified in excisional biopsies. We stage these tumors using the dimensions of the largest focus and a minimum of 2 mm between each foci to define multifocality. The cases are followed up for a median of 7 yr with no episodes of tumor recurrence or metastasis. We also show that the prevalence of residual preinvasive (20%) and invasive disease (5%) on repeat excision/surgery are comparable to data available for unifocal IA1 cases. Our study supports the hypothesis that multifocal lesions should be staged according to largest individual focus of invasion and we emphasize the importance of meticulous specimen handling to appropriately identify multifocal tumors. In addition, our analysis suggests that outcomes are comparable to unifocal lesions and supports the hypothesis that they may be managed in a similar manner.
Subject(s)
Carcinoma, Squamous Cell/classification , Uterine Cervical Neoplasms/classification , Adult , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Cervix Uteri/pathology , Cervix Uteri/surgery , Colposcopy , Female , Humans , Hysterectomy , Middle Aged , Neoplasm Staging , Pregnancy , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/surgeryABSTRACT
AIM: To determine whether sampling one section, which includes the anterior and posterior cervical lips in hysterectomy specimens, provides the best prospect for detecting stromal invasion in hysterectomy specimens for endometrial cancers. METHODS: To assess the most likely section in which cervical stromal invasion was identified in 29 cases. RESULTS: Cervical stromal invasion was detected in first section in 75.8% cases, whereas 24.1% detected in random sections other than first section. CONCLUSION: Cervical stromal invasion is most likely to be identified in one section taken in the midline, which includes anterior and posterior lips. However, in a significant number of cases, this one section missed invasion, which was detected in other random cervical sections. Therefore, sampling of one block (anterior and posterior) from the cervix is insufficient for detecting cervical stromal invasion for endometrial cancer.
Subject(s)
Cervix Uteri/pathology , Endometrial Neoplasms/pathology , Endometrial Neoplasms/surgery , Hysterectomy/methods , Specimen Handling/methods , Adult , Female , Frozen Sections , Humans , Neoplasm Invasiveness , Neoplasm Staging , Specimen Handling/standardsABSTRACT
Molecular human papillomavirus (HPV) testing is an important and developing tool for cervical disease management. However there is a requirement to develop new HPV tests that can differentiate between clinically significant and benign, clinically insignificant infection. Evidence would indicate that clinically significant infection is linked to an abortive HPV replication cycle. In particular the later stages of the replication cycle (i.e., production of late messenger (m) RNAs and proteins) appear compromised. Compared to current DNA-based tests which indicate only presence or absence of virus, detecting virus mRNAs by reverse transcriptase PCR (RT-PCR) may give a more refined insight into viral activity and by implication, clinical relevance. A novel quantitative (q)RT-PCR assay was developed for the detection of mRNAs produced late in the viral replication cycle. Initially this was validated on HPV-containing cell lines before being applied to a panel of 223 clinical cervical samples representing the cervical disease spectrum (normal to high grade). Samples were also tested by a commercial assay which detects expression of early HPV E6/E7 oncoprotein mRNAs. Late mRNAs were found in samples associated with no, low and high grade disease and did not risk-stratify HPV infection. The data reveal hidden complexities within the virus replication cycle and associated lesion development. This suggests that future mRNA tests for cervical disease may require quantitative detection of specific novel viral mRNAs.
Subject(s)
Human papillomavirus 16/genetics , Papillomavirus Infections/diagnosis , RNA, Viral/genetics , Uterine Cervical Diseases/diagnosis , Capsid Proteins/genetics , Cell Line, Transformed , Female , Genotype , Humans , Oncogene Proteins, Viral/genetics , Papillomavirus E7 Proteins/genetics , Papillomavirus Infections/virology , Polymerase Chain Reaction , RNA, Messenger/analysis , Repressor Proteins/genetics , Uterine Cervical Diseases/classificationABSTRACT
BACKGROUND: Presently, for those diagnosed with early cervical cancer who wish to conserve their fertility, there is the option of radical trachelectomy. Although successful, this procedure is associated with significant obstetric morbidity. The recurrence risk of early cervical cancer is low and in tumors measuring less than 2 cm; if the lymphatics are negative, the likelihood of parametrial involvement is less than 1%. Therefore, pelvic lymph nodes are a surrogate marker of parametrial involvement and radical excision of the parametrium can be omitted if they are negative. OBJECTIVE: The aim of this study was to report our experience of the fertility conserving management of early cervical cancer with repeat large loop excision of the transformation zone and laparoscopic pelvic lymph node dissection. METHODS: Between 2004 and 2011, a retrospective review of cases of early cervical cancer who had fertility conserving management within Glasgow Royal Infirmary was done. RESULTS: Forty-three patients underwent fertility conserving management of early cervical cancer. Forty were screen-detected cancers; 2 were stage IA1, 4 were stage IA2, and 37 were stage IB1. There were 2 central recurrences during the follow-up period. There have been 15 live children to 12 women and there are 4 ongoing pregnancies. CONCLUSIONS: To our knowledge, this is the largest case series described and confirms the low morbidity and mortality of this procedure. However, even within our highly select group, there have been 2 cases of central recurrent disease. We, therefore, are urging caution in the global adoption of this technique and would welcome a multicenter multinational randomized controlled trial.
Subject(s)
Carcinoma/surgery , Electrosurgery , Fertility , Lymph Node Excision , Uterine Cervical Neoplasms/surgery , Adult , Carcinoma/pathology , Cervix Uteri/pathology , Electrosurgery/adverse effects , Female , Humans , Laparoscopy , Pregnancy , Pregnancy Rate , Retrospective Studies , Uterine Cervical Neoplasms/pathology , Young AdultABSTRACT
Clear cell carcinomas of the uterine corpus and cervix are rare gynecological cancers with limited information regarding the pathogenesis and biology. At present, the approach to management is the same as for patients with the more common histological subtypes of endometrioid endometrial cancer and adenocarcinoma of the cervix. Surgical resection is the standard treatment for patients with early-stage disease, but there is no evidence-based approach to direct the management of patients with more advanced-stage disease at presentation or with recurrent disease. We review the epidemiology, pathology, and what is known about both uterine corpus and cervical clear cell cancers and make management recommendations.
Subject(s)
Adenocarcinoma, Clear Cell/pathology , Medical Oncology , Ovarian Neoplasms/pathology , Practice Guidelines as Topic , Uterine Neoplasms/pathology , Adenocarcinoma, Clear Cell/therapy , Combined Modality Therapy , Consensus , Female , Humans , Ovarian Neoplasms/therapy , Societies, Medical , Uterine Neoplasms/therapyABSTRACT
Squamous cell carcinoma of the ovary is a rare complication of mature cystic teratoma. The epidemiology, pathology, diagnosis, and management of this rare tumor are reviewed. Clinical characteristics, preoperative imaging, and tumor markers may help to predict malignancy preoperatively. Complete cytoreduction should be the aim of surgery. The prognosis for stage 1A disease is good, but for women with advanced or recurrent disease, it is very poor and has not improved in recent years. At present, there are insufficient data to provide clear guidance on the optimal management strategy for advanced disease, and there is a need to gain an understanding of the biology and to develop novel effective therapies. This will require coordinated international collaboration.
Subject(s)
Carcinoma, Squamous Cell/pathology , Medical Oncology , Ovarian Neoplasms/pathology , Practice Guidelines as Topic , Carcinoma, Squamous Cell/therapy , Combined Modality Therapy , Consensus , Female , Humans , Ovarian Neoplasms/therapy , Societies, MedicalABSTRACT
Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.
Subject(s)
Adenocarcinoma, Clear Cell/pathology , Medical Oncology , Ovarian Neoplasms/pathology , Practice Guidelines as Topic , Adenocarcinoma, Clear Cell/therapy , Combined Modality Therapy , Consensus , Female , Humans , Ovarian Neoplasms/therapy , Societies, MedicalABSTRACT
High-grade serous ovarian carcinoma (HGSOC) is characterised by poor outcome and extreme chromosome instability (CIN). Therapies targeting centrosome amplification (CA), a key mediator of chromosome missegregation, may have significant clinical utility in HGSOC. However, the prevalence of CA in HGSOC, its relationship to genomic biomarkers of CIN and its potential impact on therapeutic response have not been defined. Using high-throughput multi-regional microscopy on 287 clinical HGSOC tissues and 73 cell lines models, here we show that CA through centriole overduplication is a highly recurrent and heterogeneous feature of HGSOC and strongly associated with CIN and genome subclonality. Cell-based studies showed that high-prevalence CA is phenocopied in ovarian cancer cell lines, and that high CA is associated with increased multi-treatment resistance; most notably to paclitaxel, the commonest treatment used in HGSOC. CA in HGSOC may therefore present a potential driver of tumour evolution and a powerful biomarker for response to standard-of-care treatment.
Subject(s)
Cystadenocarcinoma, Serous , Ovarian Neoplasms , Humans , Female , Ovarian Neoplasms/pathology , Paclitaxel/pharmacology , Paclitaxel/therapeutic use , Centrosome/metabolism , Cystadenocarcinoma, Serous/geneticsSubject(s)
Adenoma, Villous/complications , Colonic Neoplasms/complications , Coma/etiology , Diarrhea/etiology , Dinoprostone/metabolism , Water-Electrolyte Imbalance/etiology , Adenocarcinoma, Mucinous/complications , Adenocarcinoma, Mucinous/diagnosis , Adenocarcinoma, Mucinous/surgery , Adenoma, Villous/diagnosis , Adenoma, Villous/metabolism , Adenoma, Villous/surgery , Aged , Colonic Neoplasms/diagnosis , Colonic Neoplasms/metabolism , Colonic Neoplasms/surgery , Epilepsy, Tonic-Clonic/etiology , Female , Humans , Hyponatremia/etiology , SyndromeABSTRACT
Treatment of renal angiomyolipoma (AML) seeks to reduce related complications and preserve kidney function. The purpose of this article was to perform an updated literature review on the diagnosis, therapeutic options, and criteria for invasive intervention in patients with renal AML. Computerized tomography is the standard diagnostic method for renal AML, while definitive diagnosis is made by histopathology. The management of choice in most cases is active surveillance (AS), with a clinical and imaging follow-up protocol. In high-risk cases, therapeutic management should be considered, with alternatives such as selective arterial embolization (SAE), nephron-sparing surgery (NSS), and mTOR inhibitors in selected patients. Renal AML in women of childbearing age, those with growth >0.25 cm/year, intralesional aneurysms >5 mm, and clinically significant symptoms may qualify for active treatment. Despite the limitations derived from the available evidence, it is possible to consider SAE, NSS, and the use of mTOR inhibitors as management alternatives for selected patients.